An aqueous gel fixed combination of clindamycin phosphate 1.2% and benzoyl peroxide 3.75% for the once-daily treatment of moderate to severe acne vulgaris

David M. Pariser, Phoebe Rich, Fran E. Cook-Bolden, Andrew Korotzer

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

Objective: To evaluate efficacy, safety, and tolerability of a fixed combination clindamycin phosphate 1.2% and benzoyl peroxide 3.75% (clindamycin-BP 3.75%) aqueous gel in moderate to severe acne vulgaris. Methods: A total of 498 patients, 12-40 years of age, were randomized to receive clindamycin-BP 3.75% or vehicle in a double-blind, controlled 12-week, 2-arm study evaluating safety and efficacy using inflammatory and noninflammatory lesion counts, Evaluator Global Severity Scores (EGSS) and subject self-assessment (SSA). In addition, patients completed a patient satisfaction survey (PSS), acne-specific QoL questionnaire, and assessed their facial skin for shininess/oiliness. Results: Clindamycin-BP 3.75% demonstrated statistical superiority to vehicle in reducing both inflammatory and noninflammatory lesions and acne severity. Clindamycin-BP 3.75% showed greater efficacy relative to vehicle in assessments of skin oiliness, SSA and PSS. No substantive differences were seen in cutaneous tolerability among treatment groups and no patients discontinued treatment with Clindamycm-BP 3.75% because of adverse events. Limitations: Data from controlled studies may differ from clinical practice. It is not possible to determine the contributions from the individual active ingredients. Conclusions: Clindamycin-BP 3.75% provides statistically significant greater efficacy than vehicle with a favorable safety and tolerability profile.

Original languageEnglish (US)
Pages (from-to)1083-1089
Number of pages7
JournalJournal of Drugs in Dermatology
Volume13
Issue number9
StatePublished - Jan 1 2014
Externally publishedYes

Fingerprint

Clindamycin
Acne Vulgaris
Gels
Patient Satisfaction
Safety
Skin
Benzoyl Peroxide
Therapeutics
clindamycin phosphate benzoyl peroxide combination
Surveys and Questionnaires
Self-Assessment

ASJC Scopus subject areas

  • Medicine(all)
  • Dermatology

Cite this

An aqueous gel fixed combination of clindamycin phosphate 1.2% and benzoyl peroxide 3.75% for the once-daily treatment of moderate to severe acne vulgaris. / Pariser, David M.; Rich, Phoebe; Cook-Bolden, Fran E.; Korotzer, Andrew.

In: Journal of Drugs in Dermatology, Vol. 13, No. 9, 01.01.2014, p. 1083-1089.

Research output: Contribution to journalArticle

@article{fa21b8d3944846968e590daf22f20eb5,
title = "An aqueous gel fixed combination of clindamycin phosphate 1.2{\%} and benzoyl peroxide 3.75{\%} for the once-daily treatment of moderate to severe acne vulgaris",
abstract = "Objective: To evaluate efficacy, safety, and tolerability of a fixed combination clindamycin phosphate 1.2{\%} and benzoyl peroxide 3.75{\%} (clindamycin-BP 3.75{\%}) aqueous gel in moderate to severe acne vulgaris. Methods: A total of 498 patients, 12-40 years of age, were randomized to receive clindamycin-BP 3.75{\%} or vehicle in a double-blind, controlled 12-week, 2-arm study evaluating safety and efficacy using inflammatory and noninflammatory lesion counts, Evaluator Global Severity Scores (EGSS) and subject self-assessment (SSA). In addition, patients completed a patient satisfaction survey (PSS), acne-specific QoL questionnaire, and assessed their facial skin for shininess/oiliness. Results: Clindamycin-BP 3.75{\%} demonstrated statistical superiority to vehicle in reducing both inflammatory and noninflammatory lesions and acne severity. Clindamycin-BP 3.75{\%} showed greater efficacy relative to vehicle in assessments of skin oiliness, SSA and PSS. No substantive differences were seen in cutaneous tolerability among treatment groups and no patients discontinued treatment with Clindamycm-BP 3.75{\%} because of adverse events. Limitations: Data from controlled studies may differ from clinical practice. It is not possible to determine the contributions from the individual active ingredients. Conclusions: Clindamycin-BP 3.75{\%} provides statistically significant greater efficacy than vehicle with a favorable safety and tolerability profile.",
author = "Pariser, {David M.} and Phoebe Rich and Cook-Bolden, {Fran E.} and Andrew Korotzer",
year = "2014",
month = "1",
day = "1",
language = "English (US)",
volume = "13",
pages = "1083--1089",
journal = "Journal of Drugs in Dermatology",
issn = "1545-9616",
publisher = "Journal of Drugs in Dermatology",
number = "9",

}

TY - JOUR

T1 - An aqueous gel fixed combination of clindamycin phosphate 1.2% and benzoyl peroxide 3.75% for the once-daily treatment of moderate to severe acne vulgaris

AU - Pariser, David M.

AU - Rich, Phoebe

AU - Cook-Bolden, Fran E.

AU - Korotzer, Andrew

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Objective: To evaluate efficacy, safety, and tolerability of a fixed combination clindamycin phosphate 1.2% and benzoyl peroxide 3.75% (clindamycin-BP 3.75%) aqueous gel in moderate to severe acne vulgaris. Methods: A total of 498 patients, 12-40 years of age, were randomized to receive clindamycin-BP 3.75% or vehicle in a double-blind, controlled 12-week, 2-arm study evaluating safety and efficacy using inflammatory and noninflammatory lesion counts, Evaluator Global Severity Scores (EGSS) and subject self-assessment (SSA). In addition, patients completed a patient satisfaction survey (PSS), acne-specific QoL questionnaire, and assessed their facial skin for shininess/oiliness. Results: Clindamycin-BP 3.75% demonstrated statistical superiority to vehicle in reducing both inflammatory and noninflammatory lesions and acne severity. Clindamycin-BP 3.75% showed greater efficacy relative to vehicle in assessments of skin oiliness, SSA and PSS. No substantive differences were seen in cutaneous tolerability among treatment groups and no patients discontinued treatment with Clindamycm-BP 3.75% because of adverse events. Limitations: Data from controlled studies may differ from clinical practice. It is not possible to determine the contributions from the individual active ingredients. Conclusions: Clindamycin-BP 3.75% provides statistically significant greater efficacy than vehicle with a favorable safety and tolerability profile.

AB - Objective: To evaluate efficacy, safety, and tolerability of a fixed combination clindamycin phosphate 1.2% and benzoyl peroxide 3.75% (clindamycin-BP 3.75%) aqueous gel in moderate to severe acne vulgaris. Methods: A total of 498 patients, 12-40 years of age, were randomized to receive clindamycin-BP 3.75% or vehicle in a double-blind, controlled 12-week, 2-arm study evaluating safety and efficacy using inflammatory and noninflammatory lesion counts, Evaluator Global Severity Scores (EGSS) and subject self-assessment (SSA). In addition, patients completed a patient satisfaction survey (PSS), acne-specific QoL questionnaire, and assessed their facial skin for shininess/oiliness. Results: Clindamycin-BP 3.75% demonstrated statistical superiority to vehicle in reducing both inflammatory and noninflammatory lesions and acne severity. Clindamycin-BP 3.75% showed greater efficacy relative to vehicle in assessments of skin oiliness, SSA and PSS. No substantive differences were seen in cutaneous tolerability among treatment groups and no patients discontinued treatment with Clindamycm-BP 3.75% because of adverse events. Limitations: Data from controlled studies may differ from clinical practice. It is not possible to determine the contributions from the individual active ingredients. Conclusions: Clindamycin-BP 3.75% provides statistically significant greater efficacy than vehicle with a favorable safety and tolerability profile.

UR - http://www.scopus.com/inward/record.url?scp=84907391967&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84907391967&partnerID=8YFLogxK

M3 - Article

C2 - 25226009

AN - SCOPUS:84907391967

VL - 13

SP - 1083

EP - 1089

JO - Journal of Drugs in Dermatology

JF - Journal of Drugs in Dermatology

SN - 1545-9616

IS - 9

ER -